RET and medullary thyroid gland carcinoma: In another comparative effectiveness study that performed a matching adjusted indirect comparison of selpercatinib versus cabozantinib in a cohort of patients with RET-mutation positive MTC, the ORR for selpercatinib was 82.9% versus 31.7% for cabozantinib (OR {95% CI}: 10.5 {6.2, 17.6; p < 0.0001}) [28].